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Introduction
Bladder cancer (BCa) is mainly a disease of the elderly with 
a median age at diagnosis of 73 years; and the majority of 
new diagnoses occurring in the decade between 75 and 
84 years (1). With the aging of population, BCa in the elderly 
will become even more frequent and develop in an even 
bigger public health challenge in future (2). Management 
of BCa in the elderly differs from that in younger ones both 
because of the patient reserves and his cancer behaving 
differently. For these reasons, knowledge of these peculiarities 
is essential for all physicians approaching this growing frail 
category of patients. Unfortunately, nowadays, the optimal 
treatment of BCa in this setting remains unclear and debated. 
The purpose of this review is to report the evidences on 
BCa treatment in the elderly, from non-muscle invasive 
bladder cancer (NMIBC) to advance disease, in order to help 
urologists in their everyday practice. 
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Evidence acquisition
A non-systematic Medline/PubMed literature search was 
performed with different combinations of terms as “bladder 
cancer”, “elderly”, “old”, “aged”, “BCG”, “cystectomy”, 
“chemotherapy”, “radiation therapy” and “multi-modal 
therapy”. Only articles in English language were retained 
for the analyses. Time period included articles between 
January 2000 and February 2016, with special regards 
to those published in the last 5 years. Original articles, 
reviews and editorials were selected based on their clinical 
relevance. In the literature, the definition of elderly is 
variable and based on chronological, not biological, age.
Evidence synthesis
Non-muscle invasive bladder cancer (NMIBC)
General considerations
Surgical procedures for NMIBC are usually performed 
endoscopically and are at low risk of diathesis. Also the 
anesthetic support, being generally performed with spinal 
anesthesia or sedation analgesia, has not a great impact on 
organ systems and don’t provide significant life-threatening 
risk. For these reasons surgical treatment of NMIBC is 
generally well tolerated in the elderly, even when it has to 
be repeated several times. Adjuvant intravesical therapies 
with chemotherapeutic agents, such as mitomycin C (MMC) 
or epirubicin, are usually well tolerated and have a low 
risk of side effects, mainly due to the absence of systemic 
absorption of these drugs (3). Despite these findings, it 
is clear that the length of follow up and the subsequent 
need of repeated endoscopic procedures may affect the 
quality of life of patients, especially the older ones. In order 
to reduce this therapeutic burden several alternatives to 
transurethral resection (TUR) have been proposed, based 
on the evidence that relapses after low-stage low-grade 
tumors are low grade themselves in >90% of cases, with a 
negligible risk of progression (4). Office fulguration of small 
papillary recurrences or even temporary surveillance have 
been proposed in selected cases (5,6). Also ablative intensive 
schedules of intravesical chemotherapy (CHT) with MMC 
have been tested with promising results even if further 
trials are needed in order to confirm these first findings (7). 
The treatment of low risk NMIBC in old patients does not 
usually differ from that performed in younger ones, on the 
other hand the presence of comorbidities or a poor general 
status in these patients may drive to a more conservative 
and tailored management.
Intravesical immunotherapy 
Data suggest that efficacy of BCG is reduced in the elderly 
and carries a non-negligible rate of adverse events (8,9). 
Adjuvant intravesical immunotherapy is recommended 
for NMIBC patients with intermediate and high risk of 
disease recurrence and progression (10). BCG is superior to 
chemotherapeutic agents such as MMC and epirubicin in 
preventing disease recurrence and lowers the likelihood of 
disease progression (11,12). Treatment with BCG consists 
in an induction cycle of 6 weekly instillations followed 
by a maintenance course in general (10). Many different 
maintenance schedules have been proposed. At this time 
the optimal frequency and duration of maintenance 
instillations is already unknown even if at least of one 
year on maintenance BCG is required (13). The complex 
mechanism of action of BCG is not completely clear 
yet. BCG is known to attach to the urothelium, thereby 
inducing inflammation and releasing proinflammatory 
cytokines which attract innate immune cells such as 
macrophages and neutrophil granulocytes. The following 
production of cytokines and chemokines attract T cells 
and NK cells which, through cytolysis, are responsible 
for the final anticancer effect (14). This immunologic 
cascade points out the need of an efficient activity of 
the immune system. As previously demonstrated aging 
progressively weakens immune system, due to a decline of 
the adaptative immune response (15). The influence of age 
on the response to intravesical immunotherapy in patients 
with NMIBC has been evaluated. Joudi et al. examined 
recurrence-free survival rates 2 years after the initiation 
of immunotherapy by incremental age decade. Patients 
who were 61 to 70 years old had higher recurrence-free 
survival rates compared to patients older than 80 years 
(61% versus 39%, respectively). At the multivariable analysis 
age was an independent predictor of response (8). Age was 
found to have a measurable impact in high-risk NMIBC 
as independent inverse predictor of CSS (9). Oddens et al. 
tested the efficacy of BCG in patients included in the 
EORTC Genito-Urinary (GU) Group. Two age groups 
were defined: <70 and ≥70 years. At a median follow up of 
9.2 years, patients ≥70 years had a shorter time to disease 
progression, lower overall survival and NMIBC-specific 
survival rates compared to their younger counterparts. 
BCG, however, was more effective than epirubicin for all 
the end points considered and there was no evidence that 
BCG was any less effective compared with epirubicin in 
patients ≥70 years (16). These studies well demonstrate a 
reduced response to current immunotherapeutics in the 
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elderly even if treatment with BCG remains superior to 
intravesical CHT. 
These results have to be interpreted also in the light 
of the potential side effects related to immunotherapy. 
BCG may be not so well tolerated in frail patients with 
reduced vascular, cardiac, immunologic and pulmonary 
reserves. These patients could be exposed to a higher risk 
of intravascular dissemination of tubercle bacillus and 
subsequent potential pulmonary compromise, sepsis and 
cardiovascular collapse (3). In literature there are numerous 
reports about serious adverse events in old patients (17-19). 
The age is also a major risk factor for adverse events such 
as fever, hematuria, urinary symptoms and clot retention. 
Heiner et al. reviewed a clinical course of 58 consecutive 
patients receiving BCG between 1999 and 2004. The 
complication rates were 17.6% and 48.6% for patients 
<70 and ≥70 years old, respectively. Patients who had 
complications (mean age 76.0 years) were significantly older 
than those who had no complications (70.3 years) (20). The 
non-negligible incidence of side effects has a strong impact 
on treatment compliance, leading to high discontinuation 
rates. In the report by Lamm et al. on maintenance BCG, 
only 16% of patients were able to complete the 3 years 
schedule (21). In order to solve this problem a regimen with 
a reduced dose of BCG has been proposed. The EORTC 
GU group tested the efficacy of one-third dose (1/3D) 
of BCG versus full dose (FD) regimen with 1 or 3 years 
of maintenance. The 1/3D with 1 year of maintenance 
resulted suboptimal compared to standard FD during 3 
years. No differences in toxicity between 1/3D and FD have 
been shown (22). Moreover, the administration of a reduced 
regimen in patients in which the BCG efficacy is limited 
remains questionable. In summary, even if intravesical 
BCG seems less effective in the elderly, it is still superior 
to intravesical CHT. The caveat to consider is its higher 
risk of adverse events and therefore the need to manage the 
elderly closely for them. 
New experimental conservative therapies
High risk patients intolerant to BCG or failing it have to 
be counseled for radical cystectomy (RC). However, major 
surgery in the elderly could be too risky or unfeasible, 
mainly due to the high rates of age-related comorbidities. 
In selected cases, the physician has to consider other 
conservative therapies. Nowadays, device assisted therapies 
as electromotive drug administration (EMDA) and 
chemohyperthermia are considered by guidelines as still 
oncologically marginal and to be only tested in clinical 
trials. However, efficacy results of device assisted therapies 
in NMIBC are promising. The early results of these 
approaches are very promising with an acceptable eater 
of side effects making them a probable alternative in well 
selected patients, specifically in the frail elderly (23-25). 
Therefore studies assessing the role of device assisted 
therapies in the elderly should be encouraged, as it could 
become an effective therapy in this setting.
Muscle invasive bladder cancer (MIBC)
MIBC is an aggressive tumor with a poor prognosis; the 
5- and 10-year overall survival rates are around 65% and 
45% respectively, closely related to the disease stage (10,26). 
MIBC may arise de novo or as the result of a progression 
of NMIBC. If untreated it will lead to local invasion of 
adjacent structures, hydronephrosis, incoercible hematuria, 
lymph node and distant metastases (27). Nowadays the 
only treatment with a curative intent is RC, eventually 
preceded by neoadjuvant CHT when possible. Despite 
these evidences, many older patients do not receive curative 
treatments. Analyzing the report of the SEER, Gore et al. 
found that only 21% of MIBC patients older than 65 years 
received a RC (28). The predictors for this were urologist 
choice, longer travel distances and residence in rural areas. 
These observations have been confirmed analyzing data 
from the USA National Cancer Database. Cystectomy rate 
was 55% in patients younger than 70 years, 45% in those 
70 to 79 years, and it decreased to 21% in those older than 
79 years. Half of patients older than 85 years received no 
treatment (29). Reasons for denying old patients major 
surgery are multi-factorial, but they are mainly based on 
the perception that many patients will not tolerate RC and 
urinary diversion because of age and comorbidities. For 
this reason, an integrate and multidisciplinary approach to 
this category of patients is mandatory. The evaluation has 
to be run by the urologist, oncologist, radiotherapist and 
geriatricians.
Geriatric evaluation
This evaluation is essential and has to be performed 
in order to identify the best treatment for every single 
patient with MIBC. It could provide information not only 
about treatment decision but also about preoperative and 
postoperative care, as well as the risk of complications after 
surgery or any other therapies. The geriatric evaluation 
has to be individualized and has to take into consideration 
every aspects of patient’s life. Ideally it has to answer to 
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the following questions: how is the nutritional status of 
the patient? What is his level of mobility? How is his 
social support system? How many medications does he 
take every day? How are his cognitive functions (1)? To 
help the physician in this evaluation several assessment 
tools have been developed, such as the G8 and the Flemish 
version of the Triage Risk Screening Tool (fTRST) (1,30). 
These prediction tools could help the physician in the 
treatment planning and in calculating the risk of treatment-
associated adverse events as well as 90-day morbidity 
and mortality (31). Moreover, they are useful to mitigate 
subjective confounders that could influence the clinicians’ 
decision process. As clearly emerged, when approaching a 
geriatric patient with MIBC, physicians have to consider 
the physiological and not only the chronological age of the 
subject. 
Open radical cystectomy (RC)
RC represents the standard in the treatment of MIBC 
and has to be proposed even to elderly patients as there 
is no accepted oncological equivalent alternative to date. 
Analyzing the association of treatment strategy on survival in 
octogenarians, RC shows to have the greatest risk reduction 
in death from BCa and death from any cause among the 
primary treatment modalities (32). However it is true that 
elderly go worse oncologically after RC. Nielsen et al. 
found that higher age at RC was associated with extravesical 
disease and pathological upstaging and, subsequently, 
to higher risk of disease recurrence and cancer-specific 
and overall mortality (33). Similarly, Resorlu et al. 
reported a decreasing in 5-year cancer-specific survival 
rates with age advancing (P<0.001) (26,34). This could be 
due to several reasons. With age, tumor cells could change 
their grown pattern increasing their biological potential and 
the host’s immune system progressively loses its efficacy. 
Moreover, other conditions may influence these results, such 
as a delay in performing RC (33), a decrease administration 
of neoadjuvant or adjuvant therapies and/or decrease 
performance of lymphadenectomy (3). In conclusion, when 
diagnosing a MIBC or a high risk NMIBC in a patient fit 
for major surgery at the multidisciplinary evaluation, he 
still has to be recommended for RC as the primary option, 
irrespective of his chronological age. 
Minimal invasive radical cystectomy (RC)
Laparoscopic and robot-assisted radical cystectomy (LRC 
and RARC) are becoming more widely used. They seem 
not oncological inferior but their benefits in safety and 
convalescence have not been fully proven yet (35,36). 
Oncological quality of care indicators such as the number 
of removed lymph nodes and soft tissue surgical margins 
seem not to be affected by the approach even if adjusted 
comparative analyses are lacking. Taken together, LRC and 
RARC provide decrease blood loss and transfusion rates, 
similar intraoperative complications and decrease hospital 
stays at the cost of longer operative times. For these 
reasons, LRC and RARC have been suggested to potentially 
benefit the elderly. Winters et al. retrospectively evaluate a 
monocentric series of 87 patients >75 years who underwent 
to RC (58 open, 29 robotic). RARC had significant longer 
operative times while blood loss and mean hospital stays 
were significantly improved after adjustment for the 
effects of standard features in multivariable analysis (37). 
Guillotreau et al. compared the perioperative outcomes 
of LRC and RARC in patients younger and older than 
70 years. Intraoperative and postoperative complication 
rates were similar and conversion to an open procedure 
was only 4% for both. Surprisingly mean hospital stay was 
significantly lower in older patients. Authors concluded 
that LRC and RARC does not have worse perioperative 
outcomes and could be offered to elderly patients (38). 
Node dissection
Pelvic lymph-node extended dissection (PLND) has to be 
performed in all patients undergoing RC because its role 
in staging, management, and survival (35). Nevertheless, 
still around 25% of patients undergoing RC do not 
receive PLND (39). This is even more true in the elderly 
population (40). This is probably because of the thought to 
reduce operative morbidity and length. Such assumptions 
would undermine the reason and efficacy of RC. Not to say 
that the elderly are undertreated by giving them a worse 
procedure based on misjudged risk benefit calculations. 
We strongly believed that elderly patients should not be 
withheld a potentially beneficial PLND only because of 
their chronological age. 
Urinary diversion
Ileal conduit (IC) is the most performed urinary diversion 
in the elderly. Wuethrich et al. reviewed a single center 
series of 244 patients over 75 years who underwent RC 
between 2000 and 2013. Overall, 17% of patients received 
an ileal orthotopic bladder substitution (OBS), 78% an 
IC and 5% an ureterocutaneostomy (UCST). The 90-day 
complication rate was 54.3%, 56.7% and 63.6% in OBS, 
IC and UCST respectively (41). These differences may be 
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attributed to different patients’ selection; in fact, patients 
receiving OBS had significantly lower pT stages compared 
with those receiving IC or UST. Not only the presence of 
advanced cancer but also the longer operative time of OBS, 
and the consequent stress on each organ system, could 
influence the selection of patients. For these reasons elderly 
patients are more frequent offered an IC rather than an 
OBS. The choice for IC in older patients varies from 72% 
to 87%, depending on the series (3). Again, the preoperative 
evaluation is mandatory to identify which patients could 
benefit from an OBS: this diversion could be offered to 
selected patients with low comorbidities and low disease 
stage. Conversely, IC could be offered to the majority 
of patients, being technically easier, more reproducible, 
quicker, and with low impact on perioperative and outcomes 
renal function. 
Cutaneous ureterostomy (UCST) represents a great 
opportunity in the frail poor performing elderly patients. 
UCST does not require bowel isolation and manipulation 
and allows to perform an extraperitoneal RC (42,43). 
Moreover, it is simpler and less time-consuming compared 
to the other diversions. It is reported that UCST has a 
shorter hospital stay, less blood loss and lower intraoperative 
complication rate, compared to IC (44). UCST, therefore, 
could be a simplified alternative choice for unfit and frail 
patients. 
Complications of radical cystectomy (RC)
In the last two decades perioperative mortality of RC has 
dropped from 10% to 3% in high volume centers. Still, 
surgical complications are more than 60% in contemporary 
series regardless of age. Major complications and 
reoperations rates are around 10% and 3%, respectively. 
Age and ASA score are independent predictors of high 
grade complications (45). Nevertheless, comorbidities and 
functional status seem to be better predictors than age alone 
for complications of major surgery. Froehner et al. reviewed 
complications and mortality rates after RC in the elderly. 
Total complications rate was 72% versus 64% in older and 
younger group; major complications rate was on the other 
hand not different (17% vs. 13%). However there is a lack of 
standardized reporting criteria that lead to under-reporting, 
wide variations between series (i.e., incidence of postoperative 
ileus rates range from 2% to 32%) and/or missing 
complications (mainly delirium and disorientation) (46). 
Perioperative mortality rates are, however, clearly higher 
in the elderly. Schiffmann et al. reviewed the mortality 
rates after RC analyzing more than 5,000 patients 
from the SEER database. Ninety-day mortality rates 
resulted 6.4%, 10.1% and 14.8% in age groups 65–69, 
70–79 and ≥80 years, respectively (P<0.001). Predictors of 
perioperative mortality were age (OR 2.4 in patients ≥80 years) 
and Charlson comorbidity index (CCI) (47). These 
perioperative mortality rates are higher than those reported 
at centers of excellence; there is, indeed, a well-known 
relationship between hospital volume and outcomes of RC. 
In conclusion, to reduce morbidity and mortality of RC, 
elderly patients should be referred to high volume centers 
with expertise in RC. 
Chemotherapy (CHT)
Neoadjuvant chemotherapy (CHT)
Current international guidelines recommend neoadjuvant 
CHT for all T2–T4a, cN0M0 BCa (35). Moreover, 
neoadjuvant CHT should always be a cisplatin-based 
combination therapy and, therefore, it is not recommended 
in patients ineligible for cisplatin. It is difficult to investigate 
the usage of neoadjuvant CHT in the elderly because 
of the lack of data in this group of patients. Trials about 
CHT, indeed, have been usually performed in healthier 
and younger patients. Moreover, it is well-known that one 
of the major limitations is the impaired renal function, 
making cisplatin too toxic. This is a common reality in 
the older population, who suffers from a decrease in renal 
function. Dash et al. found an impaired renal function in 
16%, 36% and 68% of patients with MIBC in age groups 
60–69, 70–79, and ≥80 years, respectively (48). For these 
reasons the majority of older patients could be unfit for 
neoadjuvant CHT or may be less likely to receive optimal 
regimen of CHT. Galsky et al. defined the criteria for 
cisplatin eligibility and proposed the ineligibility for 
patients with one of the following: ECOG PS of 2 (KPS 
of 60–70), creatinine clearance <60 mL/min, New York 
Heart Association class III, grade 2 or greater hearing loss, 
grade 2 or greater neuropathy (1). Age is not included 
in the definition but it is clear that a great percentage of 
patients >75 years may be not eligible for this therapy. 
Even in suitable patients, a single complication occurrence 
may be disastrous, leading to long hospitalization and 
compromising the functional reserves and the possibility 
to undergoing the main therapy that is the surgery. 
Concluding, nowadays, neoadjuvant CHT in the elderly 
has to be proposed to well selected patients with optimal 
performance status and low comorbidities rate (i.e., Galsky 
criteria) (1). New trials on the use of neoadjuvant CHT 
in the old population are needed in order to better define 
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which patient could benefit from this therapy. 
Adjuvant chemotherapy (CHT) and CHT alone
Adjuvant CHT is recommended in some patients with 
pT3–4 and/or N positive disease (35). As for neoadjuvant 
CHT, also in the adjuvant setting, CHT has to be based 
on cisplatin and, subsequently, has the same limitations 
of use in the elderly. This is even truer after a debilitating 
operation that RC still is. At this time, there are no studies 
focused on adjuvant CHT in the elderly and no definitive 
conclusions can be made. 
CHT is the treatment of choice in metastatic BCa 
setting. Cisplatin-based CHT is the preferred first-line 
treatment in metastatic BCa and patients should not be 
excluded only for their chronological age (1). Several 
other schedules have been proposed for patients ineligible 
to cisplatin. The EORTC group tested two carboplatin-
based regimens of CHT (gemcitabine/carboplatin vs. 
methotrexate/carboplatin/vinblastine) in a randomized 
phase II/III trial. The authors showed no significant 
differences in efficacy between the two regimens but 
higher incidence of severe toxicity in patients treated with 
methotrexate/carboplatin/vinblastine, making gemcitabine/
carboplatin the reference treatment in patients ineligible for 
cisplatin (49). 
Radiotherapy alone
External beam radiotherapy alone is not recommended as 
primary therapy for MIBC and should be considered as a 
therapeutic option only when the patient is unfit for RC or 
in cases of multimodality bladder-sparing approach. The 
feasibility of pelvic radiation alone with a curative intent 
in an elderly population with MIBC and in poor general 
conditions (CCI >2) was firstly established in 2002. In this 
study, 45 unfit patients were treated with radiation fields 
encompassing bladder and grossly involved lymph-nodes. 
Treatment was considered safe and achieved a 3- and 5-year 
OS of 36% and 19.5%, respectively; with a median survival 
of 21.5 months (50). A recent study reported similar results 
but included patients with T1 to T4 BCa, making difficult 
to compare this population to MIBC patients. Concluding, 
nowadays the role of radiation therapy with a curative intent 
in the elderly is limited and has to be reserved to patients 
unsuitable for surgery and trimodal therapy (TMT). 
Bladder saving trimodal therapy (TMT)
TMT combines radical TURB, CHT and external beam 
radiation therapy. This treatment should be proposed 
to patients unfit for surgery or asking a bladder sparing 
technique but eligible for CHT with a curative intent. 
CHT is usually performed with radiosensitising drugs 
such as cisplatin or MMC plus 5-fluorouracil, even if 
other schedules have also been investigated. TMT leads to 
favorable oncological results if given in an optimal setting: 
a recent meta-analysis reported a complete response after 
TMT in 78% of treated patients. After 5 years 79% of 
patients retained their bladder and 56% were alive (51). 
However, to date, no prospective trials comparing TMT 
to RC have been performed. TMT has also been tested 
in a cohort of 24 patients >70 years (median age 79 years). 
All patients completed the radiation treatment cycle and 
19 patients tolerated all the 4 cycles of CHT. The CSS and 
OS at 3 years were 71% and 61%, respectively. Moreover, 
75% of surviving patients were disease-free and had a 
functioning bladder (52). These results are promising and 
further studies have to be performed in elderly patients with 
MIBC and unfit for RC, for whom TMT could become an 
alternative with curative intent. 
Conclusions
(I) In the literature, the definition of elderly is variable 
and based on chronological, not biological, age;
(II) In the treatment decision the evaluation of 
chronological age is not determinant compared to 
performance status that is biological age; 
(III) Management of NMIBC in the elderly is relatively 
simple and doesn’t substantially differ from that 
adopted in younger patients; 
(IV) In MIBC, often a suboptimal therapy is given to 
elderly patients; 
(V) RC, when feasible, is still the standard treatment for 
MIBC;
(VI) The administration of CHT in the elderly is difficult 
due to their low functional reserves;
(VII) More focus is needed in this steadily growing 
segment of our population in order to allow high 
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